Carregant...
CRISPR/Cas9 gene editing for curing sickle cell disease
Sickle cell disease (SCD) is the most common monogenic blood disorder marked by severe pain, end-organ damage, and early mortality. Treatment options for SCD remain very limited. There are only four FDA approved drugs to reduce acute complications. The only curative therapy for SCD is hematopoietic...
Guardat en:
| Publicat a: | Transfus Apher Sci |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8049447/ https://ncbi.nlm.nih.gov/pubmed/33455878 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.transci.2021.103060 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|